Once-daily fluticasone propionate in stable asthma: study on airway inflammation

J Asthma. 2006 Mar;43(2):107-11. doi: 10.1080/02770900500497990.

Abstract

Children with stable asthma receiving twice-daily fluticasone propionate (FP) were studied. Spirometry, exhaled nitric oxide (eNO) and sputum eosinophils were measured at baseline and 8 weeks after FP was changed to once-daily use while keeping the same total dosage. Visual analogue scores on asthma severity, symptoms, and dosing regimen preference were obtained. Twenty-nine children of mean age 10.6 years (SD 2.5) were recruited. There was significant improvement in eNO (47.1 ppb [30.3] vs. 39.9 ppb [27.1], p = 0.037), and sputum eosinophils (5.7% [6.5] vs. 2.5% [3.9], p = 0.024] after 8 weeks. All subjects preferred the once-daily dosing regimen. Once-daily FP is effective in controlling airway inflammation. This frequency of medication use is also the preferred regimen.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Androstadienes / administration & dosage*
  • Anti-Inflammatory Agents / administration & dosage*
  • Asthma / drug therapy*
  • Asthma / immunology
  • Child
  • Drug Administration Schedule
  • Female
  • Fluticasone
  • Humans
  • Male
  • Prospective Studies

Substances

  • Androstadienes
  • Anti-Inflammatory Agents
  • Fluticasone